Meeting
2022 ASCO Annual Meeting
Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy.
Authors
Or Kalchiem-Dekel
Memorial Sloan Kettering Cancer Center, New York, NY
Or Kalchiem-Dekel , Christina J. Falcon , Christine M. Bestvina , Dazhi Liu , Lauren A. Kaplanis , Clare Wilhelm , Jordan Eichholz , Guilherme Harada , Lori J. Wirth , Robert P. Lee , David Kadosh , Robin B Mendelsohn , Jessica Donington , Justin F. Gainor , Alexander E. Drilon , Jessica Jiyeong Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9080)
DOI
10.1200/JCO.2022.40.16_suppl.9080
Abstract #
9080
Poster Bd #
67
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A pooled analysis of response to selective RET inhibitors among patients with medullary thyroid cancer with M918T versus non-M918T RET mutations.
First Author: Janice Kim
Poster
2023 ASCO Genitourinary Cancers Symposium
Financial toxicity from first-line TKI plus IO therapies for advanced renal cell carcinoma.
First Author: David Joseph Benjamin
Poster
2021 ASCO Annual Meeting
Addition of selpercatinib to overcome osimertinib resistance in non-small cell lung cancer (NSCLC) with acquired RET fusion detected in ctDNA at very low allele frequency.
First Author: Leeseul Kim
Poster
2024 ASCO Genitourinary Cancers Symposium
Glutamine metabolism and VEGF analysis to elucidate and overcome the mechanism of tyrosine kinase inhibitor resistance in renal cell carcinoma.
First Author: Kento Morozumi